A Proof-of-Mechanism Study to Determine the Effect of Danicopan on C3 Levels in Participants With C3G or IC-MPGN

Clinical trial NCT03124368 · COMPLETED

Trial details

NCT number: NCT03124368
Sponsor: Alexion Pharmaceuticals, Inc.
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

C3 Glomerulonephritis Dense Deposit Disease C3 Glomerulopathy Immune Complex Mediated Membranoproliferative Glomerulonephritis Membranoproliferative Glomerulonephritis Types I, II, and III

Start date: 2017-08-09
Primary completion: 2018-12-21
Enrollment: 6

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.